Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia S Degryse, C E de Bock,S Demeyer,I Govaerts,S Bornschein,D Verbeke, K Jacobs,S Binos,D A Skerrett-Byrne,H C Murray,N M Verrills, P Van Vlierberghe,J Cools,M D DunLeukemia(2017)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要